631 related articles for article (PubMed ID: 33317597)
1. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.
Jia XH; Geng LY; Jiang PP; Xu H; Nan KJ; Yao Y; Jiang LL; Sun H; Qin TJ; Guo H
J Exp Clin Cancer Res; 2020 Dec; 39(1):284. PubMed ID: 33317597
[TBL] [Abstract][Full Text] [Related]
2. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
[TBL] [Abstract][Full Text] [Related]
3. Management of immune checkpoint inhibitor-related rheumatic adverse events.
Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
[TBL] [Abstract][Full Text] [Related]
4. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events.
Zheng K; Qiu W; Wang H; Si X; Zhang X; Zhang L; Li X
Thorac Cancer; 2020 Jun; 11(6):1746-1751. PubMed ID: 32232975
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
7. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors.
Zhong L; Wu Q; Chen F; Liu J; Xie X
Cancer Immunol Immunother; 2021 Sep; 70(9):2559-2576. PubMed ID: 33576872
[TBL] [Abstract][Full Text] [Related]
9. Management of immune checkpoint inhibitor-related dermatologic adverse events.
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
11. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
12. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system.
Li Y; Kang X; Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Liu X; Qian J; Zhang L
Thorac Cancer; 2020 Apr; 11(4):829-834. PubMed ID: 32107847
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers related to immune checkpoint inhibitors therapy.
Li N; Hou X; Huang S; Tai R; Lei L; Li S; Abuliz A; Wang G; Yang S
Biomed Pharmacother; 2022 Mar; 147():112470. PubMed ID: 35074251
[TBL] [Abstract][Full Text] [Related]
14. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
15. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
Blum SM; Rouhani SJ; Sullivan RJ
Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
[TBL] [Abstract][Full Text] [Related]
16. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
17. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Petrelli F; Grizzi G; Ghidini M; Ghidini A; Ratti M; Panni S; Cabiddu M; Ghilardi M; Borgonovo K; Parati MC; Tomasello G; Barni S; Berruti A; Brighenti M
J Immunother; 2020 Jan; 43(1):1-7. PubMed ID: 31574022
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
19. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.
Lu M; Zhang L; Li Y; Wang H; Guo X; Zhou J; Duan L; Si X; Xu Y; Zhang L
Thorac Cancer; 2020 Mar; 11(3):805-809. PubMed ID: 31970940
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.
Da Silva Lopes AM; Colomer-Lahiguera S; Mederos Alfonso N; Aedo-Lopez V; Spurrier-Bernard G; Tolstrup LK; Pappot H; Aspeslagh S; Rogiers A; Neyns B; Haanen JB; Mitchell SA; Addeo A; Michielin O; Eicher M
Eur J Cancer; 2021 Nov; 157():225-237. PubMed ID: 34536946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
